New hope for kidney patients: drug may cut relapses without Long-Term steroids

NCT ID NCT07233330

Not yet recruiting Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated May 20, 2026 · Updated 26 times

Summary

This study tests a drug called obinutuzumab in 10 adults with a kidney condition called nephrotic syndrome that keeps coming back despite standard treatments. The goal is to see if a single course can keep the disease in remission for at least 12 months without needing repeated rituximab or steroids. Participants will receive obinutuzumab infusions and be monitored for safety, relapse, and immune system changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME，IDIOPATHIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Research Centre for Rare Diseases Aldo e Cele Daccò

Ranica, BG, 24020, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NEPHROTIC SYNDROME，IDIOPATHIC